Bluebird Bio Inc. reported that new data from an ongoing phase I trial of its gene therapy, Lentiglobin, in sickle cell disease suggests that changes made to the study protocol and to manufacturing of the therapy are improving engraftment of the gene-modified stem cells. After trading as high as $161.84, company shares (NASDAQ:BLUE) ended the day Wednesday at $142.95, up $3.85, as the company detailed its third-quarter earnings and previewed clinical data it plans to present at the American Society of Hematology (ASH) meeting next month.